Mohamed S Mohamed1, Thiago C Moulin2, Helgi B Schiöth1,3. 1. Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden. 2. Functional Pharmacology Unit, Department of Neuroscience, Uppsala University, Uppsala, Sweden. thiago.moulin@neuro.uu.se. 3. Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia.
Abstract
PURPOSE: Throughout the SARS-CoV2 pandemic, multiple reports show higher percentages of hospitalization, morbidity, and mortality among men than women, indicating that men are more affected by COVID-19. The pathophysiology of this difference is yet not established, but recent studies suggest that sex hormones may influence the viral infectivity process. Here, we review the current evidence of androgen sensitivity as a decisive factor for COVID-19 disease severity. METHODS: Relevant literature investigating the role of androgens in COVID-19 was assessed. Further, we describe several drugs suggested as beneficial for COVID-19 treatment related to androgen pathways. Lastly, we looked at androgen sensitivity as a predictor for COVID-19 progression and ongoing clinical trials on androgen suppression therapies as a line of treatment. RESULTS: SARS-COV2 virus spike proteins utilize Transmembrane protease serine 2 (TMPRSS2) for host entry. Androgen receptors are transcription promoters for TMPRSS2 and can, therefore, facilitate SARS-COV2 entry. Variants in the androgen receptor gene correlate with androgen sensitivity and are implicated in diseases like androgenetic alopecia and prostate cancer, conditions that have been associated with worse COVID-19 outcomes and hospitalization. CONCLUSION: Androgen's TMPRSS2-mediated actions might explain both the low fatalities observed in prepubertal children and the differences between sexes regarding SARS-COV2 infection. Androgen sensitivity may be a critical factor in determining COVID-19 disease severity, and sensitivity tests can, therefore, help in predicting patient outcomes.
PURPOSE: Throughout the SARS-CoV2 pandemic, multiple reports show higher percentages of hospitalization, morbidity, and mortality among men than women, indicating that men are more affected by COVID-19. The pathophysiology of this difference is yet not established, but recent studies suggest that sex hormones may influence the viral infectivity process. Here, we review the current evidence of androgen sensitivity as a decisive factor for COVID-19 disease severity. METHODS: Relevant literature investigating the role of androgens in COVID-19 was assessed. Further, we describe several drugs suggested as beneficial for COVID-19 treatment related to androgen pathways. Lastly, we looked at androgen sensitivity as a predictor for COVID-19 progression and ongoing clinical trials on androgen suppression therapies as a line of treatment. RESULTS:SARS-COV2 virus spike proteins utilize Transmembrane protease serine 2 (TMPRSS2) for host entry. Androgen receptors are transcription promoters for TMPRSS2 and can, therefore, facilitate SARS-COV2 entry. Variants in the androgen receptor gene correlate with androgen sensitivity and are implicated in diseases like androgenetic alopecia and prostate cancer, conditions that have been associated with worse COVID-19 outcomes and hospitalization. CONCLUSION: Androgen's TMPRSS2-mediated actions might explain both the low fatalities observed in prepubertal children and the differences between sexes regarding SARS-COV2infection. Androgen sensitivity may be a critical factor in determining COVID-19 disease severity, and sensitivity tests can, therefore, help in predicting patient outcomes.
Authors: Andy Goren; Sergio Vaño-Galván; Carlos Gustavo Wambier; John McCoy; Alba Gomez-Zubiaur; Oscar M Moreno-Arrones; Jerry Shapiro; Rodney D Sinclair; Michael H Gold; Maja Kovacevic; Natasha Atanaskova Mesinkovska; Mohamad Goldust; Ken Washenik Journal: J Cosmet Dermatol Date: 2020-04-23 Impact factor: 2.696
Authors: Axel M Hillmer; Sandra Hanneken; Sibylle Ritzmann; Tim Becker; Jan Freudenberg; Felix F Brockschmidt; Antonia Flaquer; Yun Freudenberg-Hua; Rami Abou Jamra; Christine Metzen; Uwe Heyn; Nadine Schweiger; Regina C Betz; Bettina Blaumeiser; Jochen Hampe; Stefan Schreiber; Thomas G Schulze; Hans Christian Hennies; Johannes Schumacher; Peter Propping; Thomas Ruzicka; Sven Cichon; Thomas F Wienker; Roland Kruse; Markus M Nothen Journal: Am J Hum Genet Date: 2005-05-18 Impact factor: 11.025
Authors: M Montopoli; S Zumerle; R Vettor; M Rugge; M Zorzi; C V Catapano; G M Carbone; A Cavalli; F Pagano; E Ragazzi; T Prayer-Galetti; A Alimonti Journal: Ann Oncol Date: 2020-05-06 Impact factor: 32.976
Authors: Carlos Gustavo Wambier; Sergio Vaño-Galván; John McCoy; Alba Gomez-Zubiaur; Sabina Herrera; Ángela Hermosa-Gelbard; Oscar M Moreno-Arrones; Natalia Jiménez-Gómez; Alvaro González-Cantero; Pablo Fonda-Pascual; Gonzalo Segurado-Miravalles; Jerry Shapiro; Bibiana Pérez-García; Andy Goren Journal: J Am Acad Dermatol Date: 2020-05-22 Impact factor: 11.527
Authors: Javier de Miguel-Diez; Ana Lopez-de-Andres; Rodrigo Jimenez-Garcia; Jose M de Miguel-Yanes; Valentin Hernández-Barrera; David Carabantes-Alarcon; Jose J Zamorano-Leon; Marta Lopez-Herranz; Ricardo Omaña-Palanco Journal: Viruses Date: 2022-06-07 Impact factor: 5.818
Authors: Andrea Crafa; Aldo E Calogero; Rossella Cannarella; Laura M Mongioi'; Rosita A Condorelli; Emanuela A Greco; Antonio Aversa; Sandro La Vignera Journal: Front Endocrinol (Lausanne) Date: 2021-06-16 Impact factor: 5.555